Search

Program-at-a-glance

To access a PDF of the program at a glance, select the image or the button below. You may find more details in the preliminary program per day.  

Read the program PDF

Read more

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

EHA European Hematology Exam 2018 Report

1. Method
a. Format
The second European Hematology Exam took place on Wednesday, June 13 in Stockholm, Sweden, and Bern, Switzerland. The Exam consisted of 100 multiple choice questions, covering all eight sections of the European Hematology Curriculum.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA

In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.

Read more